PubMed is a literature database, and a genuinely excellent one. Clinical decision support is a different, considerably harder task requiring an additional layer that selects, grades, synthesises and contextualises the literature a database like PubMed returns, and the gap between the two is where the real work of turning a search result into a clinical answer actually happens.
Five stages, one clinical question
Take a genuine clinical uncertainty and walk it through the full process any evidence-based answer requires. Stage one, convert the clinical uncertainty into a searchable question: translating "should this patient with heart failure and reduced ejection fraction be started on an SGLT2 inhibitor" into search terms that will actually retrieve the relevant literature, a structuring step every subsequent stage depends on getting right. Stage two, retrieve relevant records: running that search and pulling back the set of indexed papers that plausibly bear on the question, PubMed's core function performed well. Stage three, rank by study design and relevance: sorting retrieved records by evidentiary weight, randomised trials and systematic reviews above observational data, and by genuine relevance to the specific question rather than superficial keyword overlap. Stage four, appraise validity and effect size: reading the highest-ranked studies for methodological quality, checking whether the effect size reported is clinically meaningful rather than merely statistically significant, and noting the confidence interval's width. And stage five, reconcile the evidence with guidelines, licensing and patient circumstances: checking whether the finding aligns with current guideline recommendations, whether the specific medicine is licensed for this indication and population, and whether this particular patient's characteristics match the population the evidence was drawn from.
Where each tool actually sits in that process
Native PubMed: performs stage two, retrieval, extremely well, and stops there, leaving stages three through five entirely to the searcher. ChatGPT with the PubMed connector: extends into stages three and four to some degree, ranking and synthesising retrieved records conversationally, with the appraisal quality dependent on the underlying model's reasoning rather than a dedicated evidence-appraisal methodology, the limitation this cluster's dedicated PubMed-integration analysis treats in full. OpenEvidence: built specifically around stages three and four, evidence ranking and synthesis as its core design purpose, drawing exclusively from peer-reviewed literature with a narrower, more controlled source base than ChatGPT's broader retrieval. An evidence-summary resource, a curated guideline or systematic-review aggregator: performs stages three through five for the specific questions it has already been built to cover, at the cost of only covering a defined, curated scope rather than answering novel questions on demand. And Ask-iatroX with UK guidance: performs the full five-stage process specifically oriented toward stage five's UK-jurisdiction reconciliation, NICE, CKS and SIGN guidance, UK licensing status and UK patient-population context, the layer this cluster argues throughout is where a UK clinician's actual question ultimately needs answering.
The important nuance about search burden and omission risk
PubMed can return a genuinely large number of technically relevant papers for almost any reasonable clinical question, and an AI layer's real value lies partly in reducing that search burden, doing the work of scanning and prioritising a result set no clinician has time to read through in full during a working day. That value introduces a new responsibility rather than eliminating the old one: verifying that the model has not omitted decisive contradictory evidence while compressing a large result set into a manageable synthesis, since a confident, well-organised summary that happens to have missed the one study that changes the answer is a considerably more dangerous failure mode than an obviously incomplete one, precisely because its confidence gives no outward sign that anything was left out.
The iatroX position
This platform does not claim to have better research than PubMed, a claim that would be both inaccurate and unnecessary. iatroX's position is a clinically and jurisdictionally structured route through evidence, with links back to the supporting source at every step, doing the stage-five reconciliation work UK clinical questions specifically need and that neither raw retrieval nor a US-oriented evidence engine performs by default.
Frequently asked questions
Does adding a PubMed connector to a general AI move it meaningfully closer to a dedicated evidence engine?
It closes part of the retrieval gap specifically, stage two, while stages three through five, ranking, appraisal and reconciliation, remain dependent on the underlying model's general reasoning rather than a purpose-built evidence-appraisal methodology, a genuine but partial improvement.
Is a curated evidence-summary resource always safer than a direct database connector?
Safer within its defined scope, and narrower: a curated resource cannot answer a genuinely novel question its curation has not yet covered, while a direct connector can attempt any question at the cost of weaker built-in appraisal, a trade-off worth matching to the specific question being asked.
How should a clinician decide which of these tools to reach for on a given question?
By the stage the question actually needs help with: pure retrieval favours PubMed directly, broad literature synthesis favours a connector-equipped general AI or a specialist evidence engine, and any question with a UK-specific guideline or licensing dimension favours a UK-grounded tool specifically, since that reconciliation step is where general tools most reliably fall short.